Boston, Massachusetts, USA
Associate Professor, Medicine,
Harvard Medical School
Bladder Cancer Center
Dana-Farber Cancer Institute
Dr. Bellmunt is an attending physician at the Bladder Cancer Center at Dana-Farber Cancer Institute and Dana-Farber/Brigham and Women’s Cancer Center, Harvard University, Boston, MA.
He graduated in Medicine and Surgery from the Autonomous University of Barcelona in 1982 and obtained his PhD cum laude in 1989 from the same university. After undergoing the residency in Medical Oncology at the Hospital Universitari Vall d’Hebron in Barcelona, he completed his studies obtaining the European Certificate in Medical Oncology in London in 1989 and rotating at the Clinical Immunology Service, Division of Medical Oncology at Memorial Sloan-Kettering Cancer Center in New York in 1987 and 1989. On March 2013, Dr. Bellmunt was appointed Director of the DFCI Bladder Cancer Clinic and Associate Professor at Harvard. As a genitourinary (GU) medical oncologist, Dr. Bellmunt has been involved in, and led urothelial cancer trials for over 15 years in Europe and continues doing so at DFCI.
He has focused on the development of new systemic treatment for GU cancers, in particular bladder cancer (BC) and has been a key investigator in several trials conducted in this patient population. Recently, his research at the Bladder Cancer Center has focused on the role of checkpoint inhibitors in the treatment of GU malignancies (bladder and kidney).